Lizhu Pharmaceuticals: Application for registration and listing of JP-1366 tablets has been accepted.

Lizhu Pharmaceuticals Announcement: Recently, the company received the "Acceptance Notification Letter" issued by the National Medical Products Administration, and the domestic production drug registration of JP-1366 tablets applied by the company has been accepted by the drug regulatory authority. JP-1366 tablets are an innovative potassium ion competitive acid blocker, which can competitively block the K channel of the H, K-ATP enzyme, block the binding of K and the proton pump, inhibit the secretion of gastric acid, thereby promoting esophageal mucosal healing and improving reflux symptoms.